Gyre Therapeutics (GYRE) Other Accumulated Expenses (2011 - 2026)
Gyre Therapeutics (GYRE) reported Other Accumulated Expenses of $226000.0 for Q1 2026, down 0.88% year-over-year from $228000.0 in Q1 2025, and little changed on a QoQ basis from $227000.0 in Q4 2025.
Gyre Therapeutics (GYRE) has 16 years of Other Accumulated Expenses data on file, last reported at $226000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses fell 0.88% year-over-year to $226000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $226000.0 (down 0.88% YoY) and the FY2025 annual result came in at $227000.0, changed 0.0% from the prior year.
- Other Accumulated Expenses held at $226000.0 in Q1 2026 per GYRE's latest filing, from $227000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $4.4 million in Q1 2022 and bottomed at $118000.0 in Q4 2022.
- The 5-year median for Other Accumulated Expenses is $743000.0 (2023), against an average of $957176.5.
- The widest annual swing landed in 2022, when Other Accumulated Expenses tumbled 97.77%; it then surged 1060.17% in 2023.
- Tracing GYRE's Other Accumulated Expenses over 5 years: stood at $118000.0 in 2022, then surged by 1060.17% to $1.4 million in 2023, then plunged by 83.42% to $227000.0 in 2024, then changed by 0.0% to $227000.0 in 2025, then retreated by 0.44% to $226000.0 in 2026.
- Per Business Quant, the three latest GYRE Other Accumulated Expenses figures stand at $226000.0 (Q1 2026), $227000.0 (Q4 2025), and $228000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 226,000.00 |
| Dec 31, 2025 | 227,000.00 |
| Sep 30, 2025 | 228,000.00 |
| Jun 30, 2025 | 219,000.00 |
| Mar 31, 2025 | 228,000.00 |
| Dec 31, 2024 | 227,000.00 |
| Sep 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 1.48 Mn |
| Mar 31, 2024 | 1.36 Mn |
| Dec 31, 2023 | 1.37 Mn |
| Sep 30, 2023 | 917,000.00 |
| Jun 30, 2023 | 2.07 Mn |
| Mar 31, 2023 | 743,000.00 |
| Dec 31, 2022 | 118,000.00 |
| Sep 30, 2022 | 182,000.00 |
| Jun 30, 2022 | 948,000.00 |
| Mar 31, 2022 | 4.44 Mn |
| Dec 31, 2021 | 4.07 Mn |
| Sep 30, 2021 | 8.14 Mn |
| Jun 30, 2021 | 7.37 Mn |
| Mar 31, 2021 | 6.98 Mn |
| Dec 31, 2020 | 6.74 Mn |
| Sep 30, 2020 | 8.75 Mn |
| Jun 30, 2020 | 9.55 Mn |
| Mar 31, 2020 | 8.77 Mn |
| Dec 31, 2019 | 7.03 Mn |
| Sep 30, 2019 | 4.91 Mn |
| Jun 30, 2019 | 3.93 Mn |
| Mar 31, 2019 | 2.76 Mn |
| Dec 31, 2018 | 2.04 Mn |
| Sep 30, 2018 | 1.84 Mn |
| Jun 30, 2018 | 1.40 Mn |
| Mar 31, 2018 | 952,000.00 |
| Dec 31, 2017 | 1.32 Mn |
| Sep 30, 2017 | 1.10 Mn |
| Jun 30, 2017 | 1.46 Mn |
| Mar 31, 2017 | 730,000.00 |
| Dec 31, 2016 | 805,000.00 |
| Sep 30, 2016 | 652,000.00 |
| Jun 30, 2016 | 456,000.00 |
| Mar 31, 2016 | 401,000.00 |
| Dec 31, 2015 | 535,000.00 |
| Sep 30, 2015 | 517,000.00 |
| Dec 31, 2014 | 30,000.00 |
| Dec 31, 2013 | 52,000.00 |
| Dec 31, 2012 | 56,000.00 |
| Dec 31, 2011 | 130,000.00 |